Inhibikase Therapeutics (IKT) Change in Account Payables (2020 - 2026)
Inhibikase Therapeutics (IKT) reported Change in Account Payables of $429251.0 for Q1 2026, down 36.95% year-over-year from $680824.0 in Q1 2025, and down 20.14% quarter-over-quarter from $537526.0 in Q4 2025.
Inhibikase Therapeutics (IKT) Change in Account Payables (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Change in Account Payables data on file, last reported at $429251.0 in Q1 2026.
- Change in Account Payables for Q1 2026 came in at $429251.0, down 36.95% year-over-year; the trailing twelve-month figure through Mar 2026 was -$104746.0 (down 122.13% YoY), and the FY2025 annual result was $146827.0, down 45.98% from the prior year.
- Change in Account Payables retreated to $429251.0 in Q1 2026 per IKT's latest filing, from $537526.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $911832.0 in Q2 2025 and troughed at -$2.0 million in Q3 2025.
- A 5-year average of $23814.6 and a median of $54248.0 in 2022 frame the typical range for Change in Account Payables.
- On a YoY basis, Change in Account Payables climbed as much as 2415.21% in 2024 and fell as far as 1104.36% in 2024.
- A 5-year view of Change in Account Payables shows it stood at $369950.0 in 2022, then tumbled by 123.73% to -$87794.0 in 2023, then sank by 1104.36% to -$1.1 million in 2024, then surged by 150.84% to $537526.0 in 2025, then dropped by 20.14% to $429251.0 in 2026.
- Business Quant data shows IKT's Change in Account Payables at $429251.0 in Q1 2026, $537526.0 in Q4 2025, and -$2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -9.42 Mn |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | 429,251.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 429,251.00 |
| Mar 31, 2026 | 429,251.00 |
| Dec 31, 2025 | 537,526.00 |
| Dec 31, 2025 | 537,526.00 |
| Sep 30, 2025 | -1.98 Mn |
| Sep 30, 2025 | -1.98 Mn |
| Jun 30, 2025 | 911,832.00 |
| Jun 30, 2025 | 911,832.00 |
| Mar 31, 2025 | 680,824.00 |
| Mar 31, 2025 | 680,824.00 |
| Dec 31, 2024 | -1.06 Mn |
| Dec 31, 2024 | -1.06 Mn |
| Sep 30, 2024 | 453,434.00 |
| Sep 30, 2024 | 453,434.00 |
| Jun 30, 2024 | 396,434.00 |
| Jun 30, 2024 | 396,434.00 |
| Mar 31, 2024 | 479,267.00 |
| Mar 31, 2024 | 479,267.00 |
| Dec 31, 2023 | -87,794.00 |
| Dec 31, 2023 | -87,794.00 |